BREAKING NEWS
Woman, 20, missing after run with her dog ... Read more
Close

F&P Healthcare lifts forecast, expands Mexico plant

Last updated 09:03 18/02/2014
FPH 8.450 -0.23 -2.65%
FPH

Click for a detailed chart

Relevant offers

Industries

UN panel seeks cuts to aircraft emissions Foreign company eyes new factory in South Canterbury Springboks' mateship and French fearlessness could have undone All Blacks House values slip around New Zealand, led by Auckland: QV Twitter share price tumbles to all-time low Wired debuts ad-free website to appease ad blockers Todd family believed to be selling Winegrowers of Ara in Marlborough Falling truck movements suggest 2016 off to a "rough start" Union: Meatworkers forced into Waitangi Day work using 'mondayisation' loophole Air New Zealand investing more than $25m in precision flying technology

Fisher & Paykel Healthcare has raised its earnings guidance and brought forward plans to expand its manufacturing facility in Mexico.

The firm's annual profit for the year to March 31 is now seen at $97 million, up from the November forecast of $90-$95m.

"Demand during the second half has been very encouraging, particularly for our Simplus, Eson and Pilairo Q masks, which are used for the treatment of OSA,'' chief executive Michael Daniell said.

''Operating margin has continued to improve as a result of product mix, operating efficiency gains and manufacturing at our Mexico facility".

The company said it will expand its plant in Tijuana, Mexico, spending $4m on a fit-out to increase the manufacturing area by two thirds.

The plant is expected to be manufacturing approximately half of the company's consumable product volume within three years, F & P Healthcare said.

"We have brought forward the expansion of the Tijuana facility to ensure that we can meet anticipated demand as a result of strong customer acceptance of products such as our new masks and Optiflow oxygen therapy system,'' Daniell said.

In the United States later this year, Medicare will begin to penalise hospitals for excessive chronic respiratory patient readmissions, he said.

''We believe that this will increase the demand for our products which can help to improve care in the home for patients with chronic respiratory disease."

The company said it will continue to invest at its site in Auckland, where a number of new product platforms and associated manufacturing lines were being developed.

Ad Feedback

- Fairfax Media

Special offers

Featured Promotions

Sponsored Content